This article is more than 5 years old. Information may no longer be current.

Akorn receives OK for generic version of Neosporin

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BUFFALO GROVE, Ill. — The Food and Drug Administration granted marketing approval to Akorn for a generic formulation of neomycin and polymyxin B sulfates and bacitracin zinc as an ophthalmic ointment, the company announced in a press release. According to Akorn, the ointment is the generic equivalent to Neosporin Ophthalmic Ointment (neomycin and polymyxin B sulfates, gramicidin ophthalmic solution, King Pharmaceuticals).

The FDA approved the company’s Abbreviated New Drug Application for the drug, and Akorn anticipates its product will be commercially available beginning in the third quarter of 2004.